{"prompt": "['13.0 REFERENCES', \"1. Ganem D. KSHV infection and the pathogenesis of Kaposi's sarcoma. Ann Rev Pathol\", '2006;1:273-96.', '2. Stewart S, Jablonowski H, Goebel FD, et al: Randomized comparative trial of pegylated', 'liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related', \"Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin\", 'Oncol 16:683-91, 1998', '3. Gill PS, Miles SA, Mitsuyasu RT, et al: Phase I AIDS Clinical Trials Group (075) study of', 'adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of', \"AIDS-related Kaposi's sarcoma. AIDS 8:1695-9, 1994\", '4. Northfelt DW, Dezube BJ, Thommes JA, et al: Pegylated-liposomal doxorubicin versus', \"doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's\", 'sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16:2445-51, 1998', '5. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the', \"therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol\", '1998;16:1112-21.', '6. Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients', 'with advanced AIDS-related Kaposi sarcoma. Cancer 2002; 95:147-154.', '7. Stebbing J, Wildfire A, Portsmouth S, et al. Paclitaxel for anthracycline-resistant AIDS-related', \"Kaposi's sarcoma: clinical and angiogenic correlations. Ann Oncol 2003; 14:1660-1666.\", '8. Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated', \"liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi's\", 'sarcoma: Evidence for symptom palliation from chemotherapy. Cancer', '2010;116(16):3969-77.', '9. Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), National', 'Bureau of Statistics (NBS), Office of the Chief Government Statistician (OCGS), and ICF', 'International 2013. Tanzania HIV/AIDS and Malaria Indicator Survey 2011-12. Dar es', 'Salaam, Tanzania: TACAIDS, ZAC, NBS, OCGS, and ICF International.', 'AMC-S007 (Version 2.0) 20MAR2018', '43', 'NCI Version Date 20MAR2018']['APPENDIX I: SCHEDULE OF EVALUATIONS', 'The schedule of evaluations below applies to all participants on study. Baseline laboratory evaluations are to be conducted within', 'one', \"week before starting of therapy. Scans and x-rays must be done within two weeks prior to the start of therapy. If the participant's\", 'condition is deteriorating, laboratory evaluations should be repeated within 24 hours before initiation of the next cycle of therapy.', 'Pre-', 'Cycle', 'Cycle', 'Cycle', 'Cycle', 'Cycle', 'Cycle', 'Treatment', 'Off', 'Study', '1', '2', '3', '4', '5', '6', 'Discontinuation', 'Study', 'Informed consent', 'X', 'Demographics', 'X', 'Medical history', 'X', 'Physical exam', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Vital signs', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Height', 'X', 'Weight', 'X', 'X', 'X', 'X', 'X', 'Biopsy diagnostic of KS (fixed in formalin)', 'Xe', 'FACT-G Questionnaire', 'Xf', 'X', 'X', 'X', 'Toxicity evaluations', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Performance status', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'CBC w/diff, plts', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Serum chemistry', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Oxygen saturation', 'Xb', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Radiologic evaluation', 'X', 'X', 'X', 'Tumor measurements', 'X', 'X', 'X', 'X', 'X', 'X', 'Pregnancy test', 'Xd', 'X', 'X', 'X', 'X', 'X', 'a: Total and direct bilirubin, creatinine, SGOT [AST], SGPT [ALT].', 'b.', 'Within 14 days before enrollment', 'c.', 'Prior to chemotherapy.', 'd:', 'Serum pregnancy test (women of childbearing potential).', 'e. A skin biopsy of an area of KS will be done prior to treatment start if one has not already been done in the past.', 'f:', 'Prior to initiating treatment.', 'AMC-S007 (Version 2.0) 20MAR2018', '44', 'NCI Version Date 20MAR2018']['APPENDIX II: PERFORMANCE STATUS SCALES', 'Karnofsky Performance Scale', 'ECOG Performance Status Scale', 'Percent', 'Description', 'Grade', 'Description', 'Normal, no complaints, no', '0', '100', 'Normal activity. Fully active, able to', 'evidence of disease.', 'carry on all pre-disease performance', 'without restriction.', 'Able to carry on normal activity;', '90', 'minor signs or symptoms of', 'disease.', '1', 'Symptoms, but ambulatory.', '80', 'Normal activity with effort; some', 'Restricted in physically strenuous', 'signs or symptoms of disease.', 'activity, but ambulatory and able to', 'carry out work of a light or', 'Cares for self, unable to carry on', 'sedentary nature (e.g., light', '70', 'normal activity or to do active', 'housework, office work).', 'work.', 'Requires occasional assistance,', '2', 'In bed <50% of the time.', '60', 'but is able to care for most of', 'Ambulatory and capable of all self-', 'his/her needs.', 'care, but unable to carry out any', 'work activities. Up and about more', '50', 'Requires considerable assistance', 'than 50% of waking hours.', 'and frequent medical care.', '40', 'Disabled, requires special care and', '3', 'In bed >50% of the time. Capable of', 'assistance.', 'only limited self-care, confined to', 'bed or chair more than 50% of', '30', 'Severely disabled, hospitalization', 'waking hours.', 'indicated. Death not imminent.', 'Very sick, hospitalization', '4', '20', '100% bedridden. Completely', 'indicated. Death not imminent.', 'disabled. Cannot carry on any self-', 'care. Totally confined to bed or', '10', 'Moribund, fatal processes', 'chair.', 'progressing rapidly.', '0', 'Dead.', '5', 'Dead.', 'AMC-S007 (Version 2.0) 20MAR2018', '45', 'NCI Version Date 20MAR2018']", "completion": ""}